Wize Pharma Stock

Wize Pharma Equity

Delisted·Jan 10, 2019

The The Equity of Wize Pharma (WIZP) as of Aug 4, 2026 is -4.15 M USD. In the previous year, The Equity was 535,000.00 USD — a change of -875.33% (lower).

Equity

-4.15 MUSD

YoY

-875.33%

Last updated:

In 2026, Wize Pharma's equity was -4.15 M USD, a -875.33% increase from the 535,000.00 USD equity in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Wize Pharma Stock analysis

What does Wize Pharma do? Wize Pharma Inc. is a leading biopharmaceutical company specializing in the development and marketing of innovative products for the treatment of eye diseases. The company was founded in 1997 and is headquartered in Herzliya Pituach, Israel. It focuses on the research, development, manufacturing, and marketing of eye disease treatments. The company aims to become a leading brand in the field of eye health and offers high-quality services in eye care. Wize Pharma Inc. operates different divisions, with its main divisions being the development and marketing of eye therapeutics, including LO2A and LO2B. LO2A is an innovative therapy for dry eye, while LO2B is an intraoperative formulation used in glaucoma surgery. The company's products provide effective and sustainable solutions for the treatment of eye diseases. Wize Pharma is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Wize Pharma's Equity

Wize Pharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Wize Pharma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Wize Pharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Wize Pharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Wize Pharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Wize Pharma stock

The Equity of Wize Pharma is -4.15 M USD in 2026.

The Equity of Wize Pharma changed from 535,000.00 USD to -4.15 M USD, representing a -875.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Wize Pharma since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Wize Pharma historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Wize Pharma

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Wize Pharma